Dynamic Changes in Bone Marrow Adiposity and the Role of Estroge
Completed
- Conditions
- osteoporosis10013296
- Registration Number
- NL-OMON39889
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 21
Inclusion Criteria
female sex
regular menstrual cycle and age 18 to 50 years OR 1-5 years postmenopausal
Exclusion Criteria
contraindications to MRI scanning
use of bone-modifying or adipose tissue-modifying drugs
use of hormonal contraception
bone/adipose tissue/bone marrow diseases
contraindications to estrogen treatment (history of hormone-sensitive cancer, VTE, unexplained vaginal bleeding, endometrial hyperplasia, endometriosis, arterial thrombo-embolic diseases, acute hepatic disease or liver enzyme disorders, porfyria or known hypersensitivity to components of zumenon)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The main study parameters are the dynamic changes in bone marrow adiposity as<br /><br>assessed by QCSI measurements and the correlation of these changes to changes<br /><br>in hormones involved in the menstrual cycle (follicle stimulating hormone,<br /><br>luteinizing hormone, progesterone and estradiol). </p><br>
- Secondary Outcome Measures
Name Time Method <p>NA</p><br>